Coagulation Factor XI Inhibitor Screen, Plasma
Factor XI (FXI) deficiency, historically referred to as hemophilia C, is an autosomal inherited bleeding disorder characterized by variable bleeding risk, most commonly following trauma or surgical procedures rather than spontaneous hemorrhage. Bleeding severity correlates poorly with FXI activity level and is strongly influenced by the site of injury, with tissues that have high fibrinolytic activity, such as the oral cavity, genitourinary tract, and tonsils, being particularly susceptible. Menorrhagia may occur in affected women, often influenced by additional hemostatic factors.
In rare cases, patients with congenital FXI deficiency may develop acquired inhibitors to factor XI. These neutralizing antibodies typically arise after exposure to plasma products or FXI concentrates and have also been reported following exposure to Rh immunoglobulin. Acquired FXI inhibitors may also occur in patients without known congenital deficiency, particularly in association with autoimmune disease, malignancy, gastrointestinal disease, or advanced age. Unlike classic acquired hemophilia A, spontaneous bleeding is uncommon; however, affected patients are at high risk for prolonged or excessive bleeding during surgery or trauma.
Clinically, the presence of a factor XI inhibitor should be suspected when the activated partial thromboplastin time (aPTT) remains prolonged despite appropriate replacement therapy or fails to correct on mixing studies. Because acquired FXI inhibitors are extremely rare, laboratory confirmation using an inhibitor screen and quantification is essential to guide diagnosis and management. Identification of an inhibitor has important therapeutic implications, including avoidance of FXI concentrates, use of bypassing agents or antifibrinolytics, and consideration of immunosuppressive therapy in select cases.
- Detection of acquired inhibitors to factor XI in patients with unexplained bleeding or poor response to replacement therapy
- Evaluation of persistent aPTT prolongation that does not correct on mixing studies
- Guidance for perioperative and transfusion management in patients with suspected or confirmed factor XI inhibitors Monitoring patients at risk of inhibitor development following plasma exposure or factor XI replacement
| Factor XI Activity Assay | Reference Range |
| Adults | 55-150% |
| Neonates | > or = 10% |
| Factor XI Inhibitor Screen | Result / Reference |
| Screen Result | Negative |
| General factor Bethesda units | < or = 0.5 Bethesda units |
Platelet-poor plasma on 3.2% sodium citrate (Light-blue top) vial, 1 mL minimum.
Patient must not be receiving warfarin or heparin therapy.
Stability
- Ambient: 4 hrs.
- Refrigerated: unfavorable
- Frozen: 2 weeks
- Semin Thromb Hemost. 2009 Jun;35(4):416-25. [PMID: 19598070]
- Semin Arthritis Rheum. 2009 Aug;39(1):61-5. [PMID: 18519152]
- Nat Rev Cardiol. 2025 Nov;22(11):896-912. [PMID: 40164778]
- Cardiol Ther. 2024 Mar;13(1):1-16. [PMID: 38306010]
- Br J Haematol. 2025 Nov 16. [PMID: 41243450]